Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

t(6;22)(p21;q11)

Written2010-06Jean-Loup Huret
Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
ICD-Morpho 9811/3 B lymphoblastic leukaemia/lymphoma, NOS
ICD-Morpho 9861/3 AML with mutated NPM1; AML with mutated CEBPA; Acute myeloid leukaemia, NOS
Atlas_Id 1563
 
  t(6;22)(p21;q11) G-banding and FISH - Courtesy Claudia Haferlach.

Clinics and Pathology

Disease Hematological malignancies.
Note So far, the t(6;22)(p21;q11) is heterogeneous, and its significance remains problematic.
Phenotype / cell stem origin Four cases availble: one case was a myeloid type blast crisis of chronic myeloid leukemia (CML) in a 36-year-old male patient with a t(9;22)(q34;q11); another case was a CML aberrant translocation t(6;22)(p21;q11) without apparent involvement of chromosome 9 in a 44-year-old male patient; a third case was that of a B-cell precursor (CD10+) L1- acute lymphoblastic leukemia in a 2-year-old girl who was still in complete remission 72 months after diagnosis. A cryptic 5' ETV6 - 3' RUNX1 was found; there were accompanying anomalies, of which a +10 and a +21; the last case was a chronic lymphocytic leukemia (CLL) stage C with also a del(11q), and a del(13q).

Genes involved and Proteins

Note Genes involved, if any, are unknown.

To be noted

Additional cases are needed to delineate different entities with this anomaly:
you are welcome to submit a paper to our new Case Report section.
Case Report t(6;22)(p21;q11.2) arising at second relapse in a patient with t(8;21)-positive acute myeloid leukemia

Bibliography

Correlation between the ETV6/CBFA2 (TEL/AML1) fusion gene and karyotypic abnormalities in children with B-cell precursor acute lymphoblastic leukemia.
Fears S, Vignon C, Bohlander SK, Smith S, Rowley JD, Nucifora G.
Genes Chromosomes Cancer. 1996 Oct;17(2):127-35.
PMID 8913730
 
Philadelphia chromosome (Ph) positive chronic myelocytic leukemia (CML): frequency of additional findings.
Godde-Salz E, Schmitz N, Bruhn HD.
Cancer Genet Cytogenet. 1985 Jan 15;14(3-4):313-22.
PMID 3855371
 
Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia.
Mayr C, Speicher MR, Kofler DM, Buhmann R, Strehl J, Busch R, Hallek M, Wendtner CM.
Blood. 2006 Jan 15;107(2):742-51.
PMID 16179374
 
Effect of interferon-alpha on chromosome abnormalities in treated chronic myelogenous leukemia patients.
Tanaka H, Tanaka K, Oguma N, Ito K, Ito T, Kyo T, Dohy H, Kimura A.
Cancer Genet Cytogenet. 2004 Sep;153(2):133-43.
PMID 15350303
 

Citation

This paper should be referenced as such :
Huret, JL
t(6;22)(p21;q11)
Atlas Genet Cytogenet Oncol Haematol. 2011;15(3):297-298.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Anomalies/t0622p21q11ID1563.html


Translocations implicated (Data extracted from papers in the Atlas)

 t(6;22)(p21;q11)

External links

Mitelman databaset(6;22)(p21;q11) [Case List]    t(6;22)(p21;q11) [Association List] Mitelman database (CGAP - NCBI)
arrayMapTopo ( C42) Morph ( 9811/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMapTopo ( C42) Morph ( 9861/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
Disease databaset(6;22)(p21;q11)
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Mar 14 13:54:58 CET 2017


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.